MindMaze Therapeutics Holding SA (SIX: MMTX) announced the results of its Annual General Meeting held on June 25, 2026, in Geneva, Switzerland. Shareholders approved all proposals submitted by the Board of Directors except the proposed increase in conditional share capital, which failed to obtain the required qualified majority. This rejection signals shareholder caution regarding dilution, though the company did not disclose the specific reasons for the vote outcome.
The meeting saw the re-election of Walid Hanna, Olaf Blanke, and Martin Reiss to the Board of Directors. Additionally, Brad Hollinger, Founder, Chairman, and CEO of Vibra Healthcare, and Zach Henderson, CEO of MindMaze Therapeutics, were elected as new board members. Hollinger brings extensive healthcare leadership experience, while Henderson's election aligns with his role as the company's chief executive.
Shareholders also approved the 2025 Annual Report and financial statements, appropriation of available earnings, and discharge of board members and executive committee. The re-election of Walid Hanna as Chairman, along with elections to the Nomination and Compensation Committee, were confirmed. The independent proxy and statutory auditor were re-elected, and compensation proposals for the board and executive committee, including a consultative vote on the 2025 Compensation Report, were approved.
The AGM invitation and detailed voting results are available on the company's website. These outcomes reflect shareholder support for governance and strategic direction, despite the capital increase rejection. MindMaze Therapeutics, listed on the SIX Swiss Exchange under ticker MMTX, specializes in scalable precision neurotherapeutics using AI-driven analytics and proprietary sensors for stroke, Parkinson's disease, and other neurological disorders. Further information about the company can be found at www.mindmazetherapeutics.com.
The rejection of the conditional capital increase may impact future financing flexibility, but the company maintains a robust R&D pipeline and FDA-cleared, CE-marked products. The election of new board members, particularly Brad Hollinger, could strengthen strategic partnerships in the healthcare sector. This meeting underscores MindMaze's commitment to governance transparency as it continues operationalizing neurorestorative medicine.
